日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial

复发/难治性高危神经母细胞瘤患者的Fcγ受体多态性与SIOPEN Dinutuximab Beta长期输注试验的预后相关

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-25-0180
Lode, Holger N; Siebert, Nikolai; Valteau-Couanet, Dominique; Garaventa, Alberto; Canete, Adela; Anderson, John; Yaniv, Isaac; Ash, Shifra; Gray, Juliet; Klingebiel, Thomas; Loibner, Hans; Luksch, Roberto; Manzitti, Carla; Michon, Jean Marie; Owens, Cormac; Pötschger, Ulrike; Troschke-Meurer, Sascha; Glogova, Evgenia; Ladenstein, Ruth
信号转导
细胞生物学
发表日期：2025
文献求助 收藏

CDK inhibitors promote neuroblastoma cell differentiation and increase sensitivity to retinoic acid-a promising combination strategy for therapeutic intervention.

CDK 抑制剂可促进神经母细胞瘤细胞分化，并提高对维甲酸的敏感性——这是一种有前景的联合治疗策略

期刊:Cell Death Discovery
影响因子:7
doi:10.1038/s41420-025-02637-z
Shokraie Fatemeh, Lechermeier Larissa, Bordihn Pia, Kaps Philipp, Möller Steffen, Schulz Anna Sophie, Schneider Björn, Koczan Dirk, Roshan Samira Khanipour, Lode Holger N, Classen Carl-Friedrich, Hahn Olga, Troschke-Meurer Sascha, Maletzki Claudia
神经科学
发表日期：2025
文献求助 收藏

Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison

迪努妥昔单抗β与纳西他单抗治疗复发/难治性神经母细胞瘤患者的疗效比较：系统评价和匹配调整间接比较，这些患者病情稳定、轻微缓解或部分缓解，且伴有骨或骨髓转移。

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers17172723
Lode, Holger N; Holko, Przemysław; Wieczorek, Aleksandra; Siebert, Nikolai; Valteau-Couanet, Dominique; Garaventa, Alberto; Cañete, Adela; Anderson, John; Yaniv, Isaac; Ash, Shifra; Gray, Juliet; Luksch, Roberto; Manzitti, Carla; Troschke-Meurer, Sascha; Ebeling, Torsten; Kawalec, Paweł; Śladowska, Katarzyna; Ladenstein, Ruth L
细胞生物学
发表日期：2025
文献求助 收藏

Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study

采用包括抗GD2免疫疗法在内的多模式治疗方案治疗高危神经母细胞瘤患者的长期预后和生活质量：一项回顾性队列研究

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers17010149
Flaadt, Tim; Rehm, Jonas; Simon, Thorsten; Hero, Barbara; Ladenstein, Ruth L; Lode, Holger N; Grabow, Desiree; Nolte, Sandra; Crazzolara, Roman; Greil, Johann; Ebinger, Martin; Abele, Michael; Holzer, Ursula; Döring, Michaela; Schulte, Johannes H; Bader, Peter; Schlegel, Paul-Gerhardt; Eyrich, Matthias; Lang, Peter; Klingebiel, Thomas; Handgretinger, Rupert
细胞生物学
免疫/内分泌
发表日期：2025
文献求助 收藏

Affinity Affects the Functional Potency of Anti-GD2 Antibodies by Target-Mediated Drug Disposition.

亲和力通过靶向介导的药物处置影响抗GD2抗体的功能效力

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers17152510
Troschke-Meurer Sascha, Zumpe Maxi, Ahrenberg Peter Moritz, Ebeling Torsten, Siebert Nikolai, Grabarczyk Piotr, Lode Holger N
免疫/内分泌
发表日期：2025
文献求助 收藏

Efficacy and Safety of Anti-GD2 Immunotherapy with Dinutuximab Beta in the Treatment of Relapsed/Refractory High-Risk Neuroblastoma

抗GD2免疫疗法联合Dinutuximab Beta治疗复发/难治性高危神经母细胞瘤的疗效和安全性

期刊:Targeted Oncology
影响因子:4
doi:10.1007/s11523-025-01155-3
Wieczorek, Aleksandra; Śladowska, Katarzyna; Lode, Holger N
细胞生物学
免疫/内分泌
发表日期：2025
文献求助 收藏

Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons

Dinutuximab beta 与历史对照组在复发性神经母细胞瘤治疗中的比较：未调整和调整后的间接比较

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2025.1736165
Lode, Holger N; Holko, Przemysław; Wieczorek, Aleksandra; Śladowska, Katarzyna; Siebert, Nikolai; Valteau-Couanet, Dominique; Garaventa, Alberto; Cañete, Adela; Anderson, John; Yaniv, Isaac; Ash, Shifra; Moreno, Lucas; Gray, Juliet; Luksch, Roberto; Laureys, Genevieve; Owens, Cormac; Manzitti, Carla; Troschke-Meurer, Sascha; Kawalec, Paweł; Ladenstein, Ruth L
细胞生物学
发表日期：2025
文献求助 收藏

A New Class of Gold(I) NHC Complexes with Proapoptotic and Resensitizing Properties towards Multidrug Resistant Leukemia Cells Overexpressing BCL-2

一类新型金(I) NHC配合物，具有促凋亡和增强对过表达BCL-2的多药耐药白血病细胞敏感性的作用

期刊:Journal of Medicinal Chemistry
影响因子:6.8
doi:10.1021/acs.jmedchem.4c01117
Bannwart, Franziska; Richter, Leon F; Stifel, Simon; Rueter, Johanna; Lode, Holger N; Correia, João D G; Kühn, Fritz E; Prokop, Aram
白血病
细胞生物学
凋亡
表观遗传
发表日期：2024
文献求助 收藏

Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppression

在降低地中海贫血症造血干细胞移植毒性方面寻求平衡：输注CD3+细胞计数和免疫抑制的作用

期刊:Bone Marrow Transplantation
影响因子:5.2
doi:10.1038/s41409-024-02219-0
Meissner, Barbara; Lang, Peter; Bader, Peter; Hoenig, Manfred; Müller, Ingo; Meisel, Roland; Greil, Johann; Sauer, Martin G; Metzler, Markus; Corbacioglu, Selim; Burkhardt, Birgit; Wölfl, Matthias; Strahm, Brigitte; Kafa, Kinan; Basu, Oliver; Lode, Holger N; Gruhn, Bernd; Cario, Holger; Ozga, Ann-Kathrin; Zimmermann, Martin; Jarisch, Andrea; Beier, Rita
发育与干细胞
代谢
CD3
干细胞
细胞生物学
毒理研究
贫血
免疫/内分泌
发表日期：2024
文献求助 收藏

Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial

抗GD2抗体Dinutuximab Beta和低剂量白细胞介素2在复发性神经母细胞瘤患者单倍体相合干细胞移植后的治疗：一项多中心I/II期试验

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.22.01630
Flaadt, Tim; Ladenstein, Ruth L; Ebinger, Martin; Lode, Holger N; Arnardóttir, Helga Björk; Poetschger, Ulrike; Schwinger, Wolfgang; Meisel, Roland; Schuster, Friedhelm R; Döring, Michaela; Ambros, Peter F; Queudeville, Manon; Fuchs, Jörg; Warmann, Steven W; Schäfer, Jürgen; Seitz, Christian; Schlegel, Patrick; Brecht, Ines B; Holzer, Ursula; Feuchtinger, Tobias; Simon, Thorsten; Schulte, Johannes H; Eggert, Angelika; Teltschik, Heiko-Manuel; Illhardt, Toni; Handgretinger, Rupert; Lang, Peter
细胞生物学
发育与干细胞
干细胞
发表日期：2023
文献求助 收藏